| Effectiveness and safety of adalimumab biosimilar SB5 in inflammatory bowel disease: outcomes in originator to SB5 switch, double biosimilar switch and bio-naïve SB5 … LAAP Derikx, HW Dolby, N Plevris, L Lucaciu, CS Rees, M Lyons, ... Journal of Crohn's and Colitis 15 (12), 2011-2021, 2021 | 31* | 2021 |
| Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis LA Lucaciu, N Constantine-Cooke, N Plevris, S Siakavellas, LAAP Derikx, ... Therapeutic Advances in Gastroenterology 14, 17562848211064004, 2021 | 26 | 2021 |
| Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort B Gros, N Plevris, N Constantine‐Cooke, M Lyons, C O'Hare, C Noble, ... United European Gastroenterology Journal 11 (2), 179-188, 2023 | 13 | 2023 |
| Real-world cohort study on the effectiveness and safety of filgotinib use in ulcerative colitis B Gros, M Goodall, N Plevris, N Constantine-Cooke, AT Elford, C O’Hare, ... Journal of Crohn's and Colitis, jjad187, 2023 | 11 | 2023 |
| A review on statistical and machine learning competing risks methods K Monterrubio‐Gómez, N Constantine‐Cooke, CA Vallejos Biometrical Journal 66 (2), 2300060, 2024 | 8* | 2024 |
| Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis M Lyons, LAAP Derikx, J Fulforth, S McCall, N Plevris, PW Jenkinson, ... Alimentary Pharmacology & Therapeutics 56 (1), 67-76, 2022 | 8 | 2022 |
| Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study AT Elford, M Bishara, N Plevris, B Gros, N Constantine-Cooke, ... Frontline Gastroenterology 15 (4), 297-304, 2024 | 7 | 2024 |
| Longitudinal fecal calprotectin profiles characterize disease course heterogeneity in Crohn’s disease N Constantine-Cooke, K Monterrubio-Gómez, N Plevris, LAAP Derikx, ... Clinical Gastroenterology and Hepatology 21 (11), 2918-2927. e6, 2023 | 5 | 2023 |
| Rates, predictive factors and effectiveness of ustekinumab intensification to 4-or 6-weekly intervals in Crohn's disease LAAP Derikx, N Plevris, S Su, B Gros, M Lyons, SI Siakavellas, ... Digestive and Liver Disease 55 (8), 1034-1041, 2023 | 3 | 2023 |
| 477c HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY CW Lees, B Gros, JA Kyle, N Plevris, L Derikx, N Constantine-Cooke, ... Gastroenterology 164 (6), S-1571, 2023 | 1 | 2023 |
| Mo1782 ANALYSIS OF COLECTOMY RATES AND ADVANCED THERAPY PRESCRIBING FOR ULCERATIVE COLITIS IN LOTHIAN, SCOTLAND; AN UPDATED POPULATION BASED COHORT STUDY P Jenkinson, B Gros, N Plevris, M Lyons, L Derikx, N Constantine-Cooke, ... Gastroenterology 164 (6), S-908, 2023 | 1 | 2023 |
| P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study P Jenkinson, N Plevris, M Lyons, B Gros, L Derikx, N Constantine-Cooke, ... Journal of Crohn's and Colitis 16 (Supplement_1), i455-i456, 2022 | 1 | 2022 |
| P117 Patient perceptions about causes of flare in IBD: results from the baseline dataset of the PREdiCCt study S Siakavellas, L Derikx, L Derr, L Williams, N Plevris, P Jenkinson, ... Journal of Crohn's and Colitis 15 (Supplement_1), S209-S209, 2021 | 1 | 2021 |
| OP22 Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study L Derikx, S Siakavellas, L Derr, L Williams, P Nikolas, P Jenkinson, ... Journal of Crohn's and Colitis 15 (Supplement_1), S021-S021, 2021 | 1 | 2021 |
| P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD L Derikx, H Dolby, N Plevris, L Lucaciu, C Rees, M Lyons, S Siakavellas, ... Journal of Crohn's and Colitis 15 (Supplement_1), S353-S354, 2021 | 1 | 2021 |
| Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis B Gros, H Ross, M Nwabueze, N Constantine-Cooke, LAAP Derikx, ... Therapeutic Advances in Gastroenterology 17, 17562848241258372, 2024 | | 2024 |
| Characterising disease heterogeneity in Crohn's disease and ulcerative colitis: leveraging longitudinal biomarker profiles N Constantine-Cooke The University of Edinburgh, 2024 | | 2024 |
| Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease N Constantine-Cooke, N Plevris, K Monterrubio-Gomez, ... medRxiv, 2024.11. 08.24316916, 2024 | | 2024 |
| Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis-a six-year follow-up study B Gros, H Ross, M Nwabueze, N Constantine-Cooke, LA Derikx, M Lyons, ... JOURNAL OF CROHNS & COLITIS 18, I1582-I1584, 2024 | | 2024 |
Charlie LeesUniversity of Edinburgh在 ed.ac.uk 的电子邮件经过验证
